THERAPY DOSSIER · th-1a206d188eda

Gamma-tocotrienol

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02634606 ↗PHASE3terminated

Effects of a Tocotrienol-Enriched Fraction of Palm Oil on Serum Lipids in Hypercholesterolemic Subjects

Hypercholesterolemia

Enrolment: 13 · Results not recorded

NCT01571921 ↗PHASE1completed

Phase 1a: Randomized 2-period cross-over study comparing bioavailability of Gamma-Delta Tocotrienol (GDT) with Tocotrienol Rich Fraction (TRF) in 12 healthy subjects

Healthy Subjects

Enrolment: 12 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23941772 ↗2013Reported benefit

Gamma tocotrienol, a potent radioprotector, preferentially upregulates expression of anti-apoptotic genes to promote intestinal cell survival.

MouseRadiationCD2F1Male200 mg/kg, single dose24 h before irradiation

Model: Whole-body gamma irradiation at 11 Gy causing gastrointestinal toxicity, with jejunum sampled at 4 and 24 h

Gamma-tocotrienol given 24 h before 11 Gy whole-body irradiation up-regulated anti-apoptotic and down-regulated pro-apoptotic gene and protein expression at 4 and 24 h, with reduced TUNEL positivity and preserved jejunal crypts.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…